CN116640732A - 一种原发性耐三代tki的人非小细胞肺癌原代细胞株及其应用 - Google Patents
一种原发性耐三代tki的人非小细胞肺癌原代细胞株及其应用 Download PDFInfo
- Publication number
- CN116640732A CN116640732A CN202310240438.6A CN202310240438A CN116640732A CN 116640732 A CN116640732 A CN 116640732A CN 202310240438 A CN202310240438 A CN 202310240438A CN 116640732 A CN116640732 A CN 116640732A
- Authority
- CN
- China
- Prior art keywords
- primary
- cell strain
- tki
- lung cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 67
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 46
- 230000035772 mutation Effects 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 238000012216 screening Methods 0.000 claims abstract description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 229960001774 octenidine Drugs 0.000 claims 2
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract description 30
- 206010059866 Drug resistance Diseases 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 229960003278 osimertinib Drugs 0.000 abstract description 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 abstract description 2
- 230000008261 resistance mechanism Effects 0.000 abstract description 2
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 abstract description 2
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 86
- 210000004881 tumor cell Anatomy 0.000 description 9
- 102000001301 EGF receptor Human genes 0.000 description 8
- 108060006698 EGF receptor Proteins 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229940121645 first-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 238000012826 global research Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0688—Cells from the lungs or the respiratory tract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供了一种原发性三代TKI耐药的人非小细胞肺癌细胞株及其应用。该细胞株是从携带EGFR 21号外显子L858R突变并且三代TKI原发性耐药的患者术后肿瘤组织样本中提取所得。该细胞株除了携带EGFR 21号外显子L858R突变外,还同时携带ERBB2 17号外显子I655V、20号外显子I625V以及21号外显子I640V突变。药敏性测试结果显示,该细胞株对于AZD9291具有较高的耐药性,其IC50值为携带同样突变的H1975细胞株IC50值的11.85倍。该细胞株可用于研究L858R第三代EGFR‑TKI原发性耐药机制,探究相关信号通路,筛选和开发肿瘤耐药逆转药物,研究更有效的肿瘤治疗方法等。因此,该细胞株具有较高的科研和生产应用价值。
Description
技术领域
本发明涉及肿瘤生物技术领域,尤其涉及一种原发性耐三代TKI的人非小细胞肺癌原代细胞株及其应用。
背景技术
肺癌是肺部最常见的恶性肿瘤,也是导致癌症死亡的主要原因之一。其中,非小细胞肺癌(NSCLC)约占肺癌总数的80%-85%。虽然手术是治疗肺癌最有效的方法,但约75%的肺癌患者在诊断时已经处于晚期,失去了手术的治疗机会。因此,肺癌5年生存率仅约为19.5%。近年来,以铂类为基础的化疗药物对NSCLC的疗效虽有提高,但无法满足进展期NSCLC的治疗需要。肿瘤分子靶向治疗不仅提高了无进展生存期,且副作用更小,迅速成为全球研究的热点之一。目前已知的肺癌相关驱动基因包括EGFR(Epidermal Growth FactorReceptor,表皮生长因子受体)、ALK、KRAS、HER2、BRAF等,其中EGFR突变在亚洲人中高达60%。近年来,吉非替尼和厄洛替尼为代表的第一代EGFR-TKI(tyrosine kinaseinhibitor,酪氨酸激酶抑制剂),是携带EGFR相关突变NSCLC患者的治疗一线选择。而在临床中,有些患者对EGFR-TKIs的治疗并不敏感,或开始对该类药物高度敏感但经过约10-14个月的中位无疾病进展生存期后最终产生耐药。奥希替尼是第三代EGFR-TKI药物,2017年在我国批准上市,现已作为针对EGFR突变、靶向药物治疗进展后检测出T790M突变的NSCLC标准治疗,在晚期肺腺癌患者治疗中显得尤为重要,但仍不可避免地在半年到一年的时间内获得耐药,并表现出恶化的特征。这些更多是获得性耐药,而针对奥希替尼原发耐药性的机理研究,目前缺少合适的原代细胞株。
因此,现有技术还有待于进一步的提升和改进。
发明内容
鉴于上述现有技术的不足,本发明的目的在于提供一种原发耐三代TKI人非小细胞肺癌原代细胞株及其应用。
一种原发性耐三代TKI人非小细胞肺癌原代细胞株,其中,将其命名为人肺癌细胞系NSCLC-007T,保藏编号为GDMCC NO:63207。
可选地,所述的原发性耐三代TKI人非小细胞肺癌原代细胞株,其中,所述细胞株NSCLC-007T携带EGFR 21号外显子L858R突变,本应对三代TKI药物敏感,但它表现出原发性耐药,原代肿瘤细胞007T对三代TKI药物的IC50是H1975细胞株IC50的11.85倍;此外,此细胞株同时携带ERBB2 17号外显子I655V、20号外显子I625V号以及21号外显子I640V突变。
可选地,所述的原发性耐三代TKI的人非小细胞肺癌原代细胞株,其中,所述细胞株NSCLC-007T在构建人非小细胞肺癌体内外奥希替尼耐药的肿瘤模型中的应用。
可选地,所述的原发性三代TKI耐药的人非小细胞肺癌原代细胞株,其中,所述细胞株NSCLC-007T在筛选逆转肿瘤耐药性的药物中的应用。
可选地,所述的原发性三代TKI耐药的人非小细胞肺癌原代细胞株,其中,所述细胞株NSCLC-007T在制备抗肿瘤药物的应用。
可选地,所述的原发性三代TKI耐药的人非小细胞肺癌原代细胞株,其中,所述细胞株NSCLC-007T在筛选抗肿瘤药物的应用。
有益效果:本发明提供了一种携带EGFR 21号外显子L858R突变且原发性耐三代TKI的人非小细胞肺癌原代细胞株NSCLC-007T,同时携带ERBB2 17号外显子I655V、20号外显子I625V号以及21号外显子I640V突变。该细胞株可以用于研究原发性三代TKI耐药人非小细胞肺癌细胞形态学及生物学特点、筛选和评估抗肿瘤药物、开发肿瘤耐药逆转药物、研究更有效的肿瘤治疗方法等。此外,该细胞株还可用于探讨原发性三代TKI耐药的机制和挖掘临床靶点。因为是原发性三代TKI耐药细胞株,相较于现有的获得性耐药细胞株具有较高的科研和生产应用价值,预期能产生良好的科研、经济和社会效益。
附图说明
图1 为原发性三代TKI耐药的人非小细胞肺癌原代细胞株NSCLC-007T外显子测序总体变异百分比图。
图2为原发性三代TKI耐药的人非小细胞肺癌原代细胞株NSCLC-007T细胞增殖曲线。
图3 为原发性三代TKI耐药的人非小细胞肺癌原代细胞株NSCLC-007T细胞迁移实验结果。
图4 为原发性三代TKI耐药的人非小细胞肺癌原代细胞株NSCLC-007T细胞药物敏感性检测实验。
图5 为原发性三代TKI耐药的人非小细胞肺癌原代细胞株NSCLC-007T细胞形态图。
具体实施方式
本发明提供一种原发性三代TKI耐药的人非小细胞肺癌原代细胞株及其应用,为使本发明的目的、技术方案及效果更加清楚、明确,以下对本发明进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明。
需要说明的是,本发明中涉及的实验测试方法均为本领域常用的方法,所用的到试剂、培养液、抗体等均为市购产品。
实施例
支持细胞的培养,准备好完全培养基DMEM+10%FBS+双抗(成分为DMEM,加入10%胎牛血清(FBS),100U/ml青霉素和100 ug/ml链霉素);将3T3-J2细胞从液氮中取出来,马上放入37℃中水浴锅中尽快解冻;将3T3-J2细胞加入5ml 完全培养基中1200 rpm/min 3min RT离心;去上清,加入1ml 完全培养基轻柔吹打均匀;加入T25培养瓶中进行培养;细胞培传代培养到拟合度达80-90%丰度后加入含有丝裂霉素C(4ug/ml)3ml 1.5 h,使其成为非增殖细胞,可作为支持细胞;去除含有药物的培养基,加入DMEM完全培养基进行培养,为下一步的的原代细胞培养作为支持细胞用。
组织消化成为单个肿瘤细胞进行培养,收集非小细胞肺癌患者术后肿瘤组织0.3×0.3×0.3cm3肿瘤组织;用95~100%(v/v)的乙醇洗分离的组织样品,再用PBS(0 .01M,pH7 .4) 洗;在2.0 ml离心管中加入1.0ml配好的胶原消化酶;将冲洗好的组织加入胶原酶中用剪刀剪碎并置于37℃水浴锅中进行消化25分钟;往消化好的组织中加入含10%的PBS终止消化;将终止消化的组织过70目筛,用PBS冲洗细胞筛;1000rpm/min 5min RT离心去除上清,加入5ml红细胞裂解液裂解5-10min;加入10ml PBS终止红细胞裂解,1200rpm/min 3min RT离心,去除上清;使用PBS洗涤1-2此,离心,加入肿瘤完全培养基轻柔吹打细胞;将细胞吸入已加有支持细胞的T25瓶子置于37℃5% CO2培养箱中进行培养; 24 h内不移动细胞培养瓶,4天换一次支持细胞;7-14天左右观察是否形成原代肿瘤细胞克隆。
原代细胞传代,在装有原代肿瘤细胞的培养瓶中吸出培养基,加入3ml PBS洗涤细胞;吸去PBS,加入3 ml EDTA细胞消化液置于37℃5% CO2培养箱中消化5min; 5 min后吸取含10%FBS的PBS终止消化,去除支持细胞,用PBS洗涤完全去除支持细胞; 吸取1ml 0.05%(质量体积比)胰酶-EDTA消化加入培养瓶中置于37℃5% CO2培养箱中消化4min,消化期间注意观察细胞消化情况;至细胞掉下来80-90%加入3 ml 含有10%FBS的PBS终止胰酶消化反应;吸取细胞置于15 ml离心管中以2000rpm/min 3min RT进行离心,去除上清;细胞按照要求以1:2、1:3、1:4、1:5传代于细胞培养瓶中,或冻存或用于其他实验。
实施例2 细胞增殖实验,用胰酶将上述实施例1制备得到的原代肿瘤细胞消化成单细胞悬液并计数;将原代细胞按照每孔 1000 个细胞,铺入 96 孔板中,每组 6 孔;每隔24 小时加入 10ul CCK8 试剂,37℃孵育 2 小时后酶标仪检测吸光度,连续检测 4 天。增殖曲线如图2所示。
实施例3细胞形态学观察,及本发明的耐奥希替尼人非小细胞肺癌细胞株原代肿瘤细胞株种于25cm2培养瓶中,待生长至对数期,置倒置相差显微镜下观察活细胞形态并拍照,如图5所示,本发明所提供的耐奥希替尼的人非小细胞肺癌细胞呈立体形态。
实施例4细胞迁移实验, BD基质胶(Matrigel)提前一晚从-80℃取出放置于冰上并置于4℃冰箱中溶解;
提前在细胞培养小室(Transwell 小室,corning,8um)中铺入100μL浓度为50 μg/uL基质胶,放入37℃培养箱中,使其凝固(2小时以上);
用含0.25%EDTA胰酶消化实施例1中的来源于人非小细胞肺癌的细胞株(原代肿瘤细胞)制成细胞悬液并计数,用无血清的细胞培养基重悬细胞,将1×105的细胞悬液(即含有1×105个细胞)加入小室上层,小室下层加入 800μL 肿瘤完全培养基,放入细胞培养箱中培养 24小时;
将小室取出,弃掉培养基,用棉签将小室上部的基质胶及细胞擦净,小室上下各加入 500μL 4%多聚甲醛固定液,室温固定30分钟;
小室上下加入500μL结晶紫,染色15分钟,弃掉结晶紫,清水漂洗小室后垫支晾干;
使用刀片将小室的上室膜切下,使用盖玻片压片于载玻片上,显微镜下统计穿过基质胶的细胞数,得到细胞迁移率。同时,以正常的肺上皮细胞做对比,结果如图3所示,与正常的肺上皮细胞(N)对比,NSCLC-007T(原代肿瘤细胞)的迁移能力显著上调,说明NSCLC-007T具有高侵袭性实验结果如图3所示,与正常的肺上皮细胞(N)对比,NSCLC 007T原代细胞株的迁移能力显著上调。
实施例5外显子测序总体变异检测,采用Qiagen DNeasy Blood&Tissue Kit试剂盒对样本进行DNA提取。使用Covaris M220 Focused-ultrasonicator (Covaris)对DNA进行打断后构建测序文库。采用安捷伦SureSelect Human All Exon V6 Kit对每个样本进行捕获,结果如图1所示:其中indel为插入缺失,外显子(exonic)突变占插入缺失的8.33%(数目为733),内含子(intronic)突变占插入缺失的65.34%,其他突变占插入缺失的26.33%;SNP是单核苷酸多态性(指在基因组水平上由单个核苷酸的变异所引起的DNA序列多态性),其中外显子(exonic)突变占34.22%(数目为24037),内含子(intronic)突变占34.22%,同义单核苷酸突变(synonymous_SNV)占18.21%,其他突变占12.49%。
实施例6 细胞药物敏感性检测,将对数期生长的H1975细胞株和NSCLC 007T细胞株分别配置成每孔2000细胞;待细胞贴壁后吸去培养基,分别加入100ul含10uM、5uM、2.5uM、1uM、500nM、250nM、50nM、25nM、12.5nM、0nM AZD9291完全培养基,同一浓度3个复孔。加药后48小时,每孔加入10ul cck8,2小时后酶标仪检测处吸光值。其中,抑制率(%)=(对照组OD值-试验组OD值)/对照组OD值×100%;耐药指数(RI)=原代细胞IC50/对照细胞IC50。检测结果如图4所示,原代肿瘤细胞007T对第三代TKI药物的IC50是H1975细胞株IC50的11.85倍,大于10倍以上,所以NSCLC 007T是临床上获得的原发性三代TKI耐药的人非小细胞肺癌原代细胞株。
综上所述,本发明提供的一种原发性三代TKI耐药的人非小细胞肺癌原代细胞株,该细胞株NSCLC-007T携带EGFR 21号外显子L858R突变,本应对三代TKI药物敏感,但其原发性耐药,同时携带ERBB2 17号外显子I655V、20号外显子I625V号以及21号外显子I640V突变,具有较强的迁移能力,该细胞株可以用于研究三代TKI耐药人非小细胞肺癌细胞形态学及生物学特点、研究肿瘤耐药机制、分析抗肿瘤药物敏感性及筛选和评估抗肿瘤药物、开发肿瘤耐药逆转药物、研究更有效的肿瘤治疗方法等,因为是原发性耐药细胞株,未被其他因素影响,对耐药的机理研究更为直接,相较于现有的获得性耐药细胞株具有较高的科研和生产应用价值,预期能产生良好的科研、经济和社会效益。
应当理解的是,本发明的应用不限于上述的举例,对本领域普通技术人员来说,可以根据上述说明加以改进或变换,所有这些改进和变换都应属于本发明所附权利要求的保护范围。
Claims (7)
1. 一种原发性三代TKI耐药的人非小细胞肺癌原代细胞株,其特征在于,将其命名为人肺癌细胞系NSCLC-007T,保藏编号为GDMCC NO:63207。
2.根据权利要求1所述的原发性三代TKI耐药的人非小细胞肺癌原代细胞株,其特征在于,所述细胞株NSCLC-007T携带EGFR 21号外显子L858R突变,三代TKI耐药。
3.根据权利要求1所述的原发性三代TKI耐药的人非小细胞肺癌原代细胞株,同时携带ERBB2 17号外显子I655V、20号外显子I625V号以及21号外显子I640V突变。
4.根据权利要求1所述的耐奥希替尼的人非小细胞肺癌细胞株,其特征在于,所述细胞株NSCLC-007T在构建人非小细胞肺癌体内外奥希替尼耐药的肿瘤模型中的应用。
5.根据权利要求1所述的耐三代TKI的人非小细胞肺癌细胞株,其特征在于,所述细胞株NSCLC-007T在筛选逆转肿瘤耐药性的药物中的应用。
6.根据权利要求1所述的耐三代TKI的人非小细胞肺癌细胞株,其特征在于,所述细胞株NSCLC-007T在制备抗肿瘤药物的应用。
7.根据权利要求1所述的耐三代TKI的人非小细胞肺癌细胞株,其特征在于,所述细胞株NSCLC-007T在筛选抗肿瘤药物的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310240438.6A CN116640732A (zh) | 2023-03-14 | 2023-03-14 | 一种原发性耐三代tki的人非小细胞肺癌原代细胞株及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310240438.6A CN116640732A (zh) | 2023-03-14 | 2023-03-14 | 一种原发性耐三代tki的人非小细胞肺癌原代细胞株及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116640732A true CN116640732A (zh) | 2023-08-25 |
Family
ID=87617597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310240438.6A Pending CN116640732A (zh) | 2023-03-14 | 2023-03-14 | 一种原发性耐三代tki的人非小细胞肺癌原代细胞株及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116640732A (zh) |
-
2023
- 2023-03-14 CN CN202310240438.6A patent/CN116640732A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hao et al. | Characterization of distinct populations of carcinoma-associated fibroblasts from non–small cell lung carcinoma reveals a role for ST8SIA2 in cancer cell invasion | |
Buess et al. | Tumor-Endothelial interaction links the CD44+/CD24-phenotype with poor prognosis in early-stage breast cancer | |
CN106834486B (zh) | 骨肉瘤分子诊疗标志物及其应用 | |
AU2013229764A1 (en) | Adhesion signatures | |
US20230184744A1 (en) | INTERTUMORAL HOMOGENEITY DETERMINED BY MiCK ASSAY | |
CN109694852B (zh) | 一种人胶质瘤原代细胞及其体外分离培养方法和应用 | |
US20140206559A1 (en) | Assay for metastatic potential of tumor cells | |
CA2507496A1 (en) | Molecular determinants of myeloma bone disease and uses thereof | |
CN116445412A (zh) | 一种l858r突变三代tki耐药的人非小细胞肺癌细胞株及其应用 | |
CN116496988A (zh) | 一种人肺腺鳞癌pd1抗体获得性耐药原代细胞株及其应用 | |
CN111139298B (zh) | 4-LncRNA分子标签在肺癌预后评估中的应用 | |
CN116640732A (zh) | 一种原发性耐三代tki的人非小细胞肺癌原代细胞株及其应用 | |
Lee et al. | A functionally robust phenotypic screen that identifies drug resistance-associated genes using 3D cell culture | |
CN115011697A (zh) | Alyref在前列腺癌治疗和评估中的应用 | |
CN108165627B (zh) | 一种诊治盆腔脱垂的分子标志物 | |
CN106811532B (zh) | Acta1作为舌鳞癌诊治标志物的用途 | |
CN113122638B (zh) | 一种hsa-novel_circ_0006787分子在肝癌治疗中的应用 | |
CN108918874A (zh) | MiR-210在胶质瘤中相关靶点预测的实验方法 | |
CN105987897B (zh) | 一种血管内皮抑制素生物学活性的检测方法 | |
CN108114283A (zh) | 生物标志物muc21在骨肉瘤诊断和治疗中的应用 | |
TWI703215B (zh) | 用於預測藥物功效之活體外診斷方法 | |
CN114134118B (zh) | 一种永生化人喉环后区细胞及其构建方法 | |
CN108179181B (zh) | Rdx基因在临床用药中的应用 | |
CN107058499A (zh) | 一种用于肺腺癌诊治的分子标志物 | |
CN105256064B (zh) | Csf2基因及其表达产物的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |